Equal-WT
WhaleScore 2.0
?
REDMILE GROUP, LLC
SAN FRANCISCO CA
Investment Advisor
Hedge Fund
Activist Investor
Redmile Group is based out of San Francisco. Redmile Group is a hedge fund with 27 clients and discretionary assets under management (AUM) of $6,473,965,022 (Form ADV from 2024-07-03). Their last reported 13F filing for Q3 2024 included $1,697,433,149 in managed 13F securities
and a top 10 holdings concentration of 43.98%. Redmile Group's largest holding is Krystal Biotech Inc with shares held of 810,245. Whalewisdom has at least 77 13F filings, 47 13D filings, 265 13G filings, and 143 Form 4 filings
Business Description
Redmile Group, LLC, a Delaware limited liability company, provides investment management, advisory, and sub-advisory services to investment vehicles exempt from registration under the Investment Company Act of 1940. The firm was founded in March 2007 and is managed by Jeremy Green, the principal owner.
The firm's business model involves recommending services from portfolio companies to other portfolio companies, which may result in fees, commissions, servicing payments, and/or discounts to the firm, its affiliates, or a portfolio company. This practice creates a conflict of interest, as the firm has an incentive to maintain goodwill with existing and prospective portfolio companies, even if the recommended products or services are not the best available. The benefits received by the portfolio company providing the service may outweigh those received by the fund and its portfolio companies receiving the service.
Investment Strategy
The Firm utilizes a fundamental research approach to identify product cycles and investment themes before they become mainstream. This research process involves various avenues, including contacts with physicians, focus outside the United States, dialogue with companies, attendance at medical conferences, meetings with private companies, and regular dialogue within the team. The Firm also maintains proprietary models on a broad range of companies, including current and potential investments.
The Firm's investment allocation process considers factors such as a Fund's investment objectives, investment time horizon, and potential cost savings or transactional efficiencies. This process often results in non-pro rata allocation, meaning that not all Funds will participate in every investment opportunity. The Firm makes allocation decisions based on its expectations at the time of investment, but there is no guarantee that an investment will be suitable for another Fund in hindsight.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-09-30
Top Buys (13F)
Name | % Change |
---|---|
BNTX BioNTech SE ADR | 1.08% |
ORKA Oruka Therapeutics I | 0.59% |
ATXS Astria Therapeutics | 0.2% |
PEN Penumbra Inc | 0.16% |
ESTA Establishment Labs H | 0.08% |
2024-09-30
Top Sells (13F)
Name | % Change |
---|---|
KRYS Krystal Biotech Inc | 2.65% |
FOLD Amicus Therapeutics | 1.17% |
ALXO ALX Oncology Holding | 1.06% |
BPMC Blueprint Medicines | 0.62% |
TRDA Entrada Therapeutics | 0.48% |
2024-09-30
13F Holdings Summary
Name | $ Change |
---|---|
KRYS Krystal Biotech Inc | 8.69% |
NRIX Nurix Therapeutics, | 5.67% |
FOLD Amicus Therapeutics | 5.19% |
IMNM Immunome, Inc | 4.21% |
KYMR Kymera Therapeutics, | 3.88% |
The attached information table excludes (a) 9,322 shares of common stock of IGM BIOSCIENCES INC issued pursuant to restricted stock unit awards, (b) 11,331 shares of common stock of FATE THERAPEUTICS INC issued pursuant to restricted stock unit awards and (c) 41,461 shares of common stock of AUGMEDIX, INC. issued pursuant to restricted stock unit awards.
2024-09-30
13F Activity
Market Value | $1.70b, Prior: $1.65b |
Inflows (Outflows) as % of Total MV | (-6.5541)% |
New Purchases | 4 stocks |
Added To | 4 stocks |
Sold out of | 4 stocks |
Reduced holdings in | 33 stocks |
Top 10 Holdings % | 43.98% |
Turnover %[1] | 11.94% |
Turnover Alt %[2] | 2.55% |
Time Held Top 20 | 5.4 quarters |
Time Held Top 10 | 6.2 quarters |
Time Held All | 13.59 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-09-30